2023
Metastatic Bladder Cancer Expression and Subcellular Localization of Nectin-4 and Trop-2 in Variant Histology: A Rapid Autopsy Study
Ghali F, Vakar-Lopez F, Roudier M, Garcia J, Arora S, Cheng H, Schweizer M, Haffner M, Lee J, Yu E, Grivas P, Montgomery B, Hsieh A, Wright J, Lam H. Metastatic Bladder Cancer Expression and Subcellular Localization of Nectin-4 and Trop-2 in Variant Histology: A Rapid Autopsy Study. Clinical Genitourinary Cancer 2023, 21: 669-678. PMID: 37344281, PMCID: PMC10674028, DOI: 10.1016/j.clgc.2023.05.014.Peer-Reviewed Original ResearchConceptsMetastatic urothelial carcinomaVariant histologySacituzumab govitecanTrop-2Nectin-4Antibody-drug conjugatesMetastatic lesionsADC targetCytoplasmic stainingProminent cytoplasmic stainingMembrane stainingTrop-2 expressionCytoplasmic protein expressionMetastatic sitesAutopsy studyUrothelial carcinomaMetastatic tumorsSquamous differentiationClinical relevanceCancer expressionHistologyNeuroendocrineProtein expressionMRNA levelsProtein levels
2022
Correlative Assessment of p53 Immunostaining Patterns and TP53 Mutation Status by Next-Generation Sequencing in High-Grade Endometrial Carcinomas
Matsumoto N, Manrai P, Rottmann D, Wu X, Assem H, Hui P, Buza N. Correlative Assessment of p53 Immunostaining Patterns and TP53 Mutation Status by Next-Generation Sequencing in High-Grade Endometrial Carcinomas. International Journal Of Gynecological Pathology 2022, 42: 567-575. PMID: 36730675, DOI: 10.1097/pgp.0000000000000930.Peer-Reviewed Original ResearchConceptsHigh-grade endometrial carcinomasEndometrial carcinomaEndometrioid endometrial carcinomaTP53 mutation statusP53 immunohistochemistrySerous componentIHC staining patternNext-generation sequencing resultsNuclear overexpressionGrade 3 endometrioid endometrial carcinomaMutation statusTP53 mutationsCytoplasmic stainingStaining patternSerous endometrial carcinomaAberrant p53 expressionMixed endometrial carcinomasClinical prognosisSurrogate markerAberrant p53 proteinTherapeutic decisionsIHC patternsTP53 alterationsTumor histotypesP53 expression
2020
PD-L1 Expression in Anal Intraepithelial Neoplasia Versus. Invasive Squamous Cell Carcinoma
Monsrud A, Avadhani V, Mosunjac M, Krishnamurti U. PD-L1 Expression in Anal Intraepithelial Neoplasia Versus. Invasive Squamous Cell Carcinoma. American Journal Of Clinical Pathology 2020, 154: s67-s67. DOI: 10.1093/ajcp/aqaa161.146.Peer-Reviewed Original ResearchInvasive squamous cell carcinomaPD-L1 positivityPD-L1 expressionCases of ISCCSquamous cell carcinomaTumor proportion scoreSquamous intraepithelial lesionsPD-L1Normal mucosaIntraepithelial lesionsCell carcinomaGranular cytoplasmic stainingInvasive carcinomaProportion scoreLow-grade squamous intraepithelial lesionsCytoplasmic stainingPD-L1 positive casesAnal squamous intraepithelial lesionsHigh-grade intraepithelial lesionsGrade squamous intraepithelial lesionNuclear stainingAnal intraepithelial neoplasiaPD-L1 inhibitorsAberrant nuclear stainingAIN 2
2015
Immunohistochemical Detection of the BRAF V600E Mutant Protein in Colorectal Neoplasms
Vakiani E, Yaeger R, Brooke S, Zhou Y, Klimstra D, Shia J. Immunohistochemical Detection of the BRAF V600E Mutant Protein in Colorectal Neoplasms. Applied Immunohistochemistry & Molecular Morphology 2015, 23: 438-443. PMID: 25517872, PMCID: PMC4994705, DOI: 10.1097/pai.0000000000000116.Peer-Reviewed Original ResearchMeSH KeywordsAmino Acid SubstitutionAntibodies, NeoplasmAntibody AffinityAntibody SpecificityColonic PolypsColorectal NeoplasmsDiagnosis, DifferentialGene ExpressionHumansImmunohistochemistryMutationProto-Oncogene Proteins B-rafRetrospective StudiesSensitivity and SpecificitySpectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationConceptsBRAF V600E mutationGenetic analysisV600E mutationTumor cellsColorectal neoplasmsCytoplasmic stainingBRAF V600E mutant tumorsManagement of colorectal carcinomaBRAF V600E mutant proteinSignet ring cell typeMutation-specific antibodiesBRAF V600E proteinBRAF mutation statusHomogeneous cytoplasmic stainingWeak cytoplasmic stainingSpecificity of immunohistochemistryVE1 immunohistochemistryMutant proteinsMutation statusMutant tumorsGenetic dataDiscordant casesBRAF mutationsImmunohistochemical interpretationMass spectrometry-based assay
2012
Cytoplasmic Estrogen Receptor in Breast Cancer
Welsh AW, Lannin DR, Young GS, Sherman ME, Figueroa JD, Henry NL, Ryden L, Kim C, Love RR, Schiff R, Rimm DL. Cytoplasmic Estrogen Receptor in Breast Cancer. Clinical Cancer Research 2012, 18: 118-126. PMID: 21980134, PMCID: PMC3263348, DOI: 10.1158/1078-0432.ccr-11-1236.Peer-Reviewed Original ResearchConceptsEstrogen receptorCytoplasmic stainingCytoplasmic ERCytoplasmic estrogen receptorSpecific cytoplasmic stainingCell line seriesHuman breast tumorsQuantitative immunofluorescent analysisRoutine clinical valueRetrospective cohortTamoxifen resistanceBreast cancerLower incidencePreclinical modelsClinical valueTissue microarrayPatient controlsBreast tumorsNumber of casesClinical specimensMultiple antibodiesWestern blotAverage incidenceAntibodiesCohort
2010
Expression of glypican 3 in placental site trophoblastic tumor
Ou-Yang RJ, Hui P, Yang XJ, Zynger DL. Expression of glypican 3 in placental site trophoblastic tumor. Diagnostic Pathology 2010, 5: 64. PMID: 20868507, PMCID: PMC2954974, DOI: 10.1186/1746-1596-5-64.Peer-Reviewed Original ResearchConceptsPlacental site trophoblastic tumorPlacental site noduleInvasive cervical squamous cell carcinomaCervical squamous cell carcinomaNon-trophoblastic tumorsSquamous cell carcinomaTrophoblastic tumorCell carcinomaCytoplasmic stainingRare gestational trophoblastic neoplasmDiagnostic markerGestational trophoblastic neoplasmsGestational trophoblastic diseaseUseful diagnostic markerNon-neoplastic tissuesMembrane-bound heparan sulfate proteoglycanEndometrial adenocarcinomaUterine tumorsIntermediate trophoblastTrophoblastic diseaseTrophoblastic neoplasmsImmunohistochemical expressionHepatocellular carcinomaImmunohistochemical markersResultsEighty percent
2005
Altered Localization of p120 Catenin During Epithelial to Mesenchymal Transition of Colon Carcinoma Is Prognostic for Aggressive Disease
Bellovin DI, Bates RC, Muzikansky A, Rimm DL, Mercurio AM. Altered Localization of p120 Catenin During Epithelial to Mesenchymal Transition of Colon Carcinoma Is Prognostic for Aggressive Disease. Cancer Research 2005, 65: 10938-10945. PMID: 16322241, DOI: 10.1158/0008-5472.can-05-1947.Peer-Reviewed Original ResearchConceptsSurvival timeMesenchymal transitionLymph node metastasisColorectal cancer progressionPoor patient outcomesE-cadherinLate-stage tumorsPatient survival timePost-EMT cellsP120ctn expressionAltered localizationLymph nodesNode metastasisAggressive diseaseTumor stagePrimary tumorTumor necrosisColorectal carcinomaPatient outcomesColon carcinoma cellsE-cadherin lossCytoplasmic stainingColon carcinomaCancer progressionCarcinoma cells
2004
Expression of BAG-1 and BcL-2 Proteins Before and After Neoadjuvant Chemotherapy of Locally Advanced Breast Cancer
Pusztai L, Krishnamurti S, Cardona J, Sneige N, Esteva FJ, Volchenok M, Breitenfelder P, Kau SW, Takayama S, Krajewski S, Reed JC, Bast RC, Hortobagyi GN. Expression of BAG-1 and BcL-2 Proteins Before and After Neoadjuvant Chemotherapy of Locally Advanced Breast Cancer. Cancer Investigation 2004, 22: 248-256. PMID: 15199607, DOI: 10.1081/cnv-120030213.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsCarrier ProteinsCell DeathChemotherapy, AdjuvantDNA-Binding ProteinsDoxorubicinFemaleHumansImmunohistochemistryMiddle AgedNeoadjuvant TherapyPredictive Value of TestsPrognosisProto-Oncogene Proteins c-bcl-2Transcription FactorsTreatment OutcomeConceptsComplete pathological responsePathological responseBcl-2 expressionNeoplastic cellsBcl-2Breast cancerTissue specimensSubsequent pathological responsesAdvanced breast cancerBAG-1Breast epithelial cellsBAG-1 expressionExploratory pilot studyPrechemotherapy specimensNeoadjuvant chemotherapyClinical responseResidual tumorCytotoxic therapyPosttreatment specimensAnti-apoptotic proteinsPreoperative doxorubicinChemotherapyCytoplasmic stainingIndividual tumorsBreast tissue
2001
Tissue microarray analysis of beta-catenin in colorectal cancer shows nuclear phospho-beta-catenin is associated with a better prognosis.
Chung GG, Provost E, Kielhorn EP, Charette LA, Smith BL, Rimm DL. Tissue microarray analysis of beta-catenin in colorectal cancer shows nuclear phospho-beta-catenin is associated with a better prognosis. Clinical Cancer Research 2001, 7: 4013-20. PMID: 11751495.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsbeta CateninCadherinsCell LineCell NucleusColorectal NeoplasmsCytoplasmCytoskeletal ProteinsDogsGene Expression Regulation, NeoplasticHumansImmunohistochemistryNeoplasm StagingOligonucleotide Array Sequence AnalysisPhosphoproteinsPrognosisProportional Hazards ModelsRecombinant ProteinsReproducibility of ResultsSurvival RateTrans-ActivatorsTransfectionTreatment OutcomeConceptsOverall survivalNuclear expressionColorectal cancerSeries of patientsColorectal cancer specimensTissue microarray analysisMajority of cancersBetter prognosisClinical outcomesClinicopathological factorsImproved survivalCancer specimensTissue microarrayImmunohistochemical analysisMembranous stainingColorectal tumorigenesisCytoplasmic stainingMultivariate analysisSignificant associationCancerAdenomatous polyposis coli (APC) geneNuclear stainingBeta-catenin overexpressionOnly stageSurvival
1989
Plasminogen activator inhibitor types 1 and 2 in human trophoblasts. PAI-1 is an immunocytochemical marker of invading trophoblasts.
Feinberg RF, Kao LC, Haimowitz JE, Queenan JT, Wun TC, Strauss JF, Kliman HJ. Plasminogen activator inhibitor types 1 and 2 in human trophoblasts. PAI-1 is an immunocytochemical marker of invading trophoblasts. Laboratory Investigation 1989, 61: 20-6. PMID: 2473276.Peer-Reviewed Original ResearchConceptsPAI-2Plasminogen activator inhibitorSpecific plasminogen activator inhibitorPAI-1Villous syncytiotrophoblastHuman trophoblastsCytoplasmic localizationPlasminogen activatorRegulated productionPAI expressionCytoplasmic stainingCell surface stainingCultured cytotrophoblastsProminent cytoplasmic stainingIntervillous blood flowPlasminogen activator inhibitor type 1Activator inhibitor type 1Inhibitor type 1First trimesterActivatorProteolytic enzymesVascular remodelingVillous cytotrophoblastsBlood flowImmunohistochemical analysis
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply